Navigation Links
STAAR Surgical's Visian® ICL Surpasses 200,000 Implants

MONROVIA, Calif., Jan. 4, 2011 /PRNewswire/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that the worldwide total number of Visian® ICL implants in patients has exceeded 200,000.  Since 1994, STAAR's Implantable Collamer® Lenses (ICLs) have been used in refractive eye surgery as an alternative to LASIK.  Manufactured with STAAR's proprietary Collamer material, Visian ICLs provide a safe and effective alternative in the permanent correction of myopia, hyperopia, and in the case of the Toric ICL, astigmatism.

"This milestone demonstrates that STAAR's ICL technology continues to transform the refractive market with increased share in the global surgical market," said Barry G. Caldwell, president and CEO of STAAR Surgical. "During the last half of 2010 we began shipping the new expanded version of the Vision ICL in countries that accept CE Mark Certification.  During 2010 Visian ICL sales increased by 15%, while the LASIK segment continues to be challenged.  We are most proud of the high level of patient satisfaction delivered by STAAR's technology for placing correction in the posterior segment, which avoids problems experienced with anterior segment phakic lenses.  Of the over 200,000 ICLs implanted over the past 17 years, over 14,000 of those have been in eyes for over 10 years.  The overall safety and patient satisfaction data is very encouraging and differentiates the Visian product line from other refractive surgical options," Mr. Caldwell concluded.

The Company is focused on driving awareness of the benefits of its Visian ICL over LASIK surgery.  In the fall of 2010, STAAR initiated a direct-to-consumer marketing campaign that includes a series of seven videos that describe the features of its ICL in a funny, easily accessible manner.  STAAR, in conjunction with ophthalmologists, is rolling out these videos around the world.  In South Korea, where the ICL has captured over 10% of the refractive surgery market, STAAR's distributor has invested in a direct-to-consumer educational video which will be shown with pre-movie trailers during the first quarter.

"During 2011, it is important that we continue to make progress toward regulatory approval for the Visian Toric ICL in the United States and Japan," continued Mr. Caldwell.  "The market in Japan offers a very large opportunity for the ICL technology, particularly given the high percentage of the population who experience myopia and astigmatism.  With the Japan market for the ICL available the entire year, we expect our growth rates in 2011 to exceed our level in 2010."

About STAAR SurgicalSTAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye.  All of these lenses are foldable, which permits the surgeon to insert them through a small incision.  A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL."  A lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL."  Over 200,000 Visian ICLs have been implanted to date; to learn more about the ICL go to:  STAAR has approximately 300 full time employees and markets lenses in approximately 50 countries.  Headquartered in Monrovia, CA, it manufactures in the following locations: Nidau, Switzerland; Ichikawa City, Japan; Aliso Viejo, CA; and Monrovia, CA.  For more information, please visit the Company's website at or call 626-303-7902.  

The Visian ICL for hyperopia and Toric ICL for astigmatism have not been approved for sale in the United States.

Safe HarborAll statements in this press release that are not statements of historical fact are forward-looking statements, including statements about efforts to obtain regulatory approval in any country and expectations for growth in sales of Visian ICL products, any statements of belief; and any statements of assumptions underlying any of the foregoing. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: the broad discretion of regulators in approving medical devices in our major markets, which can require costly and time consuming research and result in the indefinite delay or denial of approval; poor global economic conditions that can depress sales of products, especially products like the ICL used in non-reimbursed elective procedures; the risk of unfavorable changes in currency exchange rates; the willingness of surgeons and patients to adopt a new product and procedure; patterns of Visian ICL use that have typically limited our penetration of the refractive surgery market; a general decline in the demand for refractive surgery, which STAAR believes has resulted from both concerns about the safety and effectiveness of laser procedures and general economic conditions; our limited capital resources and limited access to financing; and the challenge of managing our foreign subsidiaries.  CONTACT:


MediaEVC Group

EVC GroupDouglas Sherk, 415-896-6820

Chris GaleJenifer Kirtland, 415-896-2005


SOURCE STAAR Surgical Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. STAAR Surgical Reports Continued Double Digit Core Revenue Growth
2. STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS
3. STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter
4. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
5. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
6. Lilly Surpasses United Way 2010 Campaign Goal
7. Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies
8. Osteotechs MagniFuse(TM) Distributed to 68 U.S. Hospitals as Product Revenue Surpasses $1 Million
9. Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals
10. Lilly Surpasses United Way 2009 Campaign Goal
11. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
Post Your Comments:
(Date:11/25/2015)... Nov. 26, 2015  The total global healthcare industry is ... 2015-2016. Latin America has the highest ... (excluding Japan ), is second with growth ... to face increased healthcare expenditure. In 2013-2014, total government funded ... 43.5% in 2008-2009 to 41.2% in 2013-2014. In real terms, ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... The print component of “Supporting Our Caregivers” ... New York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies and ... vast social media strategy and across a network of top news sites and ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... A simply ... Jones, is an interesting show that delves into an array of issues that are ... that could benefit from open dialogue, this show is changing the subjects consumers focus ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge ... imaging in the Waterloo region. Using the Ocean Platform, family physicians can now ... their electronic medical record (EMR) without the need for redundant patient entry or ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... opinion process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits ... place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held ...
Breaking Medicine News(10 mins):